BOSTON SCIENTIFIC CORP

(c)

On February 20, 2024, Vance R. Brown, our Senior Vice President, General Counsel and Corporate Secretary entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Brown’s plan covers the sale of 33,043 shares to be acquired upon exercise of stock options. Transactions under Mr. Brown’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Brown’s plan will terminate on the earlier of December 31, 2024, or the date all shares subject to the plan have been sold.

On February 21, 2024, Daniel Brennan, our Executive Vice President and Chief Financial Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Brennan’s plan covers the sale of 112,075 shares of our common stock, including 64,454 shares to be acquired upon exercise of stock options. Transactions under Mr. Brennan’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Brennan’s plan will terminate on the earlier of December 31, 2024, or the date all shares subject to the plan have been sold.

On February 26, 2024, Jonathan Monson, ourprior Senior Vice President, Global Controller and Chief Accounting Officer until March 1, 2024, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Monson’s plan covers the sale of 16,082 shares of our common stock, including 10,000 shares to be acquired upon exercise of stock options. Transactions under Mr. Monson’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Monson’s plan will terminate on the earlier of February 1, 2025, or the date all shares subject to the plan have been sold.

On February 28, 2024, Jeffrey B. Mirviss, our Senior Vice President and President, Peripheral Interventions, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mirviss’ plan covers the sale of up to 88,888 shares of our common stock, including up to 25,086 shares to be acquired upon determination and/or vesting of performance share units and restricted share units and 33,726 shares to be acquired upon exercise of stock options. Transactions under Mr. Mirviss’ plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mirviss’ plan will terminate on the earlier of February 21, 2025, or the date all shares subject to the plan have been sold.

On February 28, 2024, Michael F. Mahoney, our Chairman and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mahoney’s plan covers the sale of 488,332 shares of our common stock, including 335,659 shares to be acquired upon exercise of stock options. Transactions under Mr. Mahoney’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mahoney’s plan will terminate on the earlier of November 8, 2024, or the date all shares subject to the plan have been sold.